What it sells
A therapeutics platform for curing inflammatory disorders
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma partners/acquirers and biotech investors (no product sold).
Workflow: what inputs become what output?
Uses patient-sample insights to develop medicines that restore immune regulation rather than suppress it, for Crohn's disease, ankylosing spondylitis and psoriasis.
Economics: what it saves and how it charges
UnverifiedDrug-development company funded by investors; value from licensing/partnering or acquiring therapeutics. Claims only 25% of patients benefit long term from current therapies.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.